Initial studies showed efficacy of JQ1 downregulating both MYC expression and Myc’s transcriptome genome-wide in Myc-addicted hematological malignancies [62,63,64], and solid cancers [65,66,67,68]. This evidence concerns the gene MYC and hematologic disorder.